Data / Drug companies / BluePoint Laboratories
BluePoint Laboratories: 332 products in the FDA NDC directory, labeler code 68001
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
BluePoint Laboratories (labeler code 68001) lists 332 products in the FDA National Drug Code Directory, covering 112 finished drugs by generic name. By type: 298 prescription drugs, 34 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 5, 2026.
The request: Watch BluePoint Laboratories (FDA labeler code 68001): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68001
- Products in commercial distribution
- 332
- Packages
- 476
- Finished drugs by generic name
- 112
- Prescription products
- 298
- Over the counter products
- 34
- Flagged as original packager
- 294 of 294 products that carry the flag
- Started marketing in the last 12 months
- 43
- Products with a marketing end date set
- 11
- Earliest marketing start
- January 3, 1995
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 314 | 94.6% |
| Over the counter monograph drugs | 12 | 3.6% |
| New drug applications (NDA) | 6 | 1.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 298 | 89.8% |
| Over the counter drugs | 34 | 10.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 79 | 23.8% |
| Tablet, film coated | 38 | 11.4% |
| Capsule | 34 | 10.2% |
| Injection, powder, lyophilized, for solution | 32 | 9.6% |
| Injection | 26 | 7.8% |
| Tablet, extended release | 25 | 7.5% |
| Injection, solution | 13 | 3.9% |
| Injection, powder, for solution | 11 | 3.3% |
| Tablet, delayed release | 9 | 2.7% |
| Tablet, film coated, extended release | 9 | 2.7% |
| Patch, extended release | 6 | 1.8% |
| Ointment | 6 | 1.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Doxorubicin hydrochloride | 68001-706 | Injection, suspension, liposomal | Generic drugs (ANDA) | October 5, 2026 |
| Doxorubicin hydrochloride | 68001-707 | Injection, suspension, liposomal | Generic drugs (ANDA) | October 2, 2026 |
| Decitabine | 68001-713 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 29, 2026 |
| Palonosetron | 68001-708 | Injection | Generic drugs (ANDA) | July 15, 2026 |
| Labetalol Hydrochloride | 68001-702 | Tablet | Generic drugs (ANDA) | June 4, 2026 |
| Nicotine Transdermal System Patch Step 1 | 68001-699 | Patch, extended release | New drug applications (NDA) | May 28, 2026 |
| Nicotine Transdermal System Patch Step 2 | 68001-698 | Patch, extended release | New drug applications (NDA) | May 28, 2026 |
| Nicotine Transdermal System Patch Step 3 | 68001-697 | Patch, extended release | New drug applications (NDA) | May 28, 2026 |
| Doxorubicin hydrochloride | 68001-704 | Injectable, liposomal | Generic drugs (ANDA) | April 2, 2026 |
| Doxorubicin hydrochloride | 68001-703 | Injectable, liposomal | Generic drugs (ANDA) | April 2, 2026 |
| Paclitaxel | 68001-705 | Injection | Generic drugs (ANDA) | April 1, 2026 |
| Teriparatide | 68001-693 | Injection | Generic drugs (ANDA) | March 19, 2026 |
| Labetalol Hydrochloride | 68001-701 | Tablet | Generic drugs (ANDA) | March 15, 2026 |
| Labetalol Hydrochloride | 68001-700 | Tablet | Generic drugs (ANDA) | March 15, 2026 |
| Cyclophosphamide | 68001-696 | Injection, powder, for solution | Generic drugs (ANDA) | March 15, 2026 |
| Cyclophosphamide | 68001-695 | Injection, powder, for solution | Generic drugs (ANDA) | March 15, 2026 |
| Cyclophosphamide | 68001-694 | Injection, powder, for solution | Generic drugs (ANDA) | March 15, 2026 |
| Metoprolol Succinate | 68001-687 | Tablet, extended release | Generic drugs (ANDA) | March 1, 2026 |
| Metoprolol Succinate | 68001-686 | Tablet, extended release | Generic drugs (ANDA) | March 1, 2026 |
| Metoprolol Succinate | 68001-685 | Tablet, extended release | Generic drugs (ANDA) | March 1, 2026 |
| Metoprolol Succinate | 68001-684 | Tablet, extended release | Generic drugs (ANDA) | March 1, 2026 |
| Nadolol | 68001-692 | Tablet | Generic drugs (ANDA) | February 25, 2026 |
| Nadolol | 68001-691 | Tablet | Generic drugs (ANDA) | February 25, 2026 |
| Nadolol | 68001-690 | Tablet | Generic drugs (ANDA) | February 25, 2026 |
| Aprepitant | 68001-668 | Capsule | Generic drugs (ANDA) | February 10, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.